Invention Grant
- Patent Title: Pyrrolopyrimidines as janus kinase inhibitors
- Patent Title (中): 吡咯并嘧啶类作为刺激激酶抑制剂
-
Application No.: US14363097Application Date: 2012-11-30
-
Publication No.: US08993756B2Publication Date: 2015-03-31
- Inventor: Sean P. Ahearn , Matthew Christopher , Christopher Dinsmore , Joon Jung , Qinglin Pu , Alexey Rivkin , Mark E. Scott , David J. Witter , Hyun Chong Woo , Brandon Cash
- Applicant: Merck Sharp & Dohme Corp.
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Patricia A. Shatynski; Laura M. Ginkel
- International Application: PCT/US2012/067152 WO 20121130
- International Announcement: WO2013/085802 WO 20130613
- Main IPC: C07D487/04
- IPC: C07D487/04 ; C07D417/04 ; C07D413/04 ; A61K31/519 ; A61P19/02 ; C07D519/00 ; C07D471/04

Abstract:
The instant invention provides compounds of formula I which are JAK3 inhibitors. Specifically, the compounds of formula I are pyrrolo[2,3-d]pyrimidine derivative compounds. The instant invention also provides methods of treating JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer, by administering the pyrrolo[2,3-d]pyrimidine-derivative compounds of formula I.
Public/Granted literature
- US20140349998A1 PYRROLOPYRIMIDINES AS JANUS KINASE INHIITORS Public/Granted day:2014-11-27
Information query